Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.16 USD | +1.48% | +57.05% | +44.29% |
May. 15 | B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating | MT |
May. 14 | Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+44.29% | 572M | C- | ||
+32.36% | 694B | C+ | ||
+29.67% | 593B | B | ||
-1.60% | 371B | C+ | ||
+20.07% | 331B | B- | ||
+6.04% | 290B | C+ | ||
+14.64% | 239B | B+ | ||
+10.22% | 209B | B- | ||
-3.27% | 209B | A+ | ||
+9.27% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- HROW Stock
- Ratings Harrow, Inc.